Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Indoramin→

Indoramin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
26844-12-2
Molecular formula
C22H25N3O
Molecular weight
347.5 g/mol
Drug class
Selective alpha-1 adrenergic receptor antagonistantihypertensive agent
Mechanism of action
Competitively blocks postsynaptic alpha-1 adrenoceptors, reducing peripheral vascular resistance. It also relaxes smooth muscle in the prostate.
Indications / reported uses
  • Treatment of hypertension under the relevant product authorisation.
  • Symptomatic relief of lower urinary tract symptoms associated with benign prostatic hyperplasia where authorised.

Sources: https://www.medicines.org.uk/emc/product/12925/smpc · https://pubchem.ncbi.nlm.nih.gov/compound/33625

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Indoramin Environmental Risk Assessment (ERA) (the Indoramin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.